2012
Ki67 expression in the primary tumor predicts for clinical benefit and time to progression on first-line endocrine therapy in estrogen receptor-positive metastatic breast cancer
Delpech Y, Wu Y, Hess KR, Hsu L, Ayers M, Natowicz R, Coutant C, Rouzier R, Barranger E, Hortobagyi GN, Mauro D, Pusztai L. Ki67 expression in the primary tumor predicts for clinical benefit and time to progression on first-line endocrine therapy in estrogen receptor-positive metastatic breast cancer. Breast Cancer Research And Treatment 2012, 135: 619-627. PMID: 22890751, DOI: 10.1007/s10549-012-2194-2.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Agents, HormonalBreast NeoplasmsBreast Neoplasms, MaleCarcinoma, Ductal, BreastDisease-Free SurvivalFemaleHumansKaplan-Meier EstimateKi-67 AntigenMaleMiddle AgedMultivariate AnalysisNeoplasm Recurrence, LocalNeoplasms, Hormone-DependentProportional Hazards ModelsReceptors, EstrogenRetrospective StudiesTreatment OutcomeConceptsFirst-line endocrine therapyEndocrine therapyMetastatic breast cancerMetastatic diseaseKi67 expressionClinical benefitPrimary tumorBreast cancerExpression groupEstrogen receptor-positive metastatic breast cancerIndependent adverse prognostic factorKaplan-Meier survival curvesClinical benefit rateKi67 expression levelsAdverse prognostic factorMedian survival timeLow Ki67 expressionBreast cancer correlatesHigh Ki67 expressionHigh clinical benefitPrognostic factorsMedian timeMetastatic recurrencePrimary cancerImmunohistochemical variables
2006
Bortezomib (VELCADE®) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits
Yang CH, Gonzalez-Angulo AM, Reuben JM, Booser DJ, Pusztai L, Krishnamurthy S, Esseltine D, Stec J, Broglio KR, Islam R, Hortobagyi GN, Cristofanilli M. Bortezomib (VELCADE®) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits. Annals Of Oncology 2006, 17: 813-817. PMID: 16403809, DOI: 10.1093/annonc/mdj131.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBone NeoplasmsBoronic AcidsBortezomibBreast NeoplasmsDisease ProgressionDisease-Free SurvivalFemaleHumansMaleMaximum Tolerated DoseMiddle AgedPleural NeoplasmsProtease InhibitorsPyrazinesReceptors, EstrogenReceptors, ProgesteroneSoft Tissue NeoplasmsSurvival RateTreatment OutcomeConceptsMetastatic breast cancerBreast cancerPlasma interleukin-6 levelsCommon grade 3Limited clinical activityClinical response ratePhase II studyInterleukin-6 levelsMedian survival timeWeek of restBroad antitumor activityStable diseaseII studyObjective responseSkin rashClinical effectsClinical benefitDisease progressionClinical activityGrade 3Pharmacodynamic dataSurvival timeMean inhibitionSingle agentResponse rate